Join the DexCom (DXCM) Securities Class Action Lawsuit

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against DexCom, Inc. (DXCM)

If you purchased or acquired DexCom, Inc. securities between July 26, 2024 and September 17, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About DexCom

DexCom is a medical device company focused on the development, manufacturing, and commercialization of continuous glucose monitoring (CGM) systems.

The company’s flagship products, including the G6 and G7 CGM systems, are designed to provide real-time glucose readings to help patients manage their condition.

The Allegations

The securities class action lawsuit alleges that DexCom and certain executives made materially false and misleading statements and failed to disclose material information about the Company’s G6 and G7 CGM devices. According to the complaint, DexCom made design modifications to the G6 and G7 sensors without prior FDA authorization.

The lawsuit further alleges that these unapproved changes affected device accuracy and subjected the Company to increased regulatory scrutiny.

According to the complaint, on March 7, 2025, DexCom filed an SEC Form 8-K disclosing that it had received a warning letter from the FDA regarding quality-control processes. Following this disclosure, DexCom’s stock declined from a closing price of $77.84 on March 7 to $70.72 on March 10, 2025, a decrease of $7.12 per share.

On March 25, 2025, the FDA published the warning letter on its website, stating that DexCom had modified the G6 and G7 sensors without prior clearance. The Company’s stock fell from $75.32 on March 24 to $72.13 on March 26, 2025, a decline of $3.19 per share.

Additional developments occurred later in the class period. On September 8, 2025, Oppenheimer downgraded DexCom’s rating from “outperform” to “perform,” citing market concerns about the G7’s performance. DexCom’s stock declined from $80.51 on September 5 to $78.00 on September 8, 2025.

Then, on September 18, 2025, an investigative report discussed safety and performance concerns associated with the G7 and referenced FDA records obtained through a Freedom of Information Act request. Following publication, DexCom’s stock fell from $76.44 on September 17 to $67.45 on September 19, 2025, a total decrease of $8.99 per share over two trading sessions.

Important Dates

• Class period: July 26, 2024 to September 17, 2025
• Complaint filed: October 27, 2025
• Lead plaintiff deadline: December 26, 2025

Your Rights and Next Steps

If you purchased or otherwise acquired DexCom securities during the class period, you may have the right to participate in the class action lawsuit. Investors who sustained losses can seek to recover their damages through this legal action.

You are not required to take any action to remain a potential class member. However, if you wish to serve as lead plaintiff, the representative party who acts on behalf of all class members, you must file a motion with the court by December 26, 2025.

Lawyers are ready to help evaluate your claim, explain your rights, and guide you through the process. Even if you choose not to become a lead plaintiff, you may still be eligible to receive a portion of any recovery if the lawsuit is successful.

You May Be Entitled to Compensation

If you purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, you may be entitled to compensation for your losses. Lawyers are available to review your transactions, explain your options, and assist you in pursuing your claim.

To find out if you qualify and to join the lawsuit, complete the form below.